Skip to content

Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.

RCT Concerning the Intention to Prescribe/Take Oral Anticoagulants for Atrial Fibrillation Depending on the Number of Risk Diagrams (w Treatment +/- w/Out Treatment), and Number of Years (1 or 5) for the Estimation of the Risk of Stroke.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02746107
Enrollment
968
Registered
2016-04-21
Start date
2016-03-31
Completion date
2016-06-30
Last updated
2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Stroke

Keywords

shared decision making, oral anticoagulant, atrial fibrillation, stroke, decision to treat

Brief summary

Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial fibrillation or the physician himself, imagining she/he has atrial fibrillation) on the intention to prescribe or not oral anticoagulation.

Detailed description

Objectives: To answer the questions: 1. Concerning the decision to prescribe (take) treatment on the basis of a decision aid, are there necessary both diagrams (that with risk without treatment, and that with risk under treatment), or it is enough only the second (risk under treatment, which normally gives all the needed information)? 2. Concerning the decision to prescribe (take) treatment, is it a difference between the effects of the presentation on decision aid of the risk of stroke for the next 1 year, and the presentation of the estimated risk of stroke for the next 5 years? 3. Is the decision different if physicians prescribe the anticoagulant treatment to patients, over if they should take it themselves? Study: 2x3 factorial randomized controlled trial (RCT) for comparison: 1. Between the decision aid with 2 images (without treatment + with treatment) and the one with 1 image (risk only with treatment) 2. Between the effect of the presentation of the stroke risk chart for 1 year and the stroke risk chart for 5 years. 3. The decision to prescribe to patients over the decision to take the treatment themselves. The comparison will be made for the spectrum of risks (scores CHA2DS2-VASC) from 1-5. Sample size: was calculated a sample of 948 participants (474 + 474) for p = 0.05, power = 80% statistical difference between decisions of 5% (from 95% to 90%). The study does not have enough power neither to compare the 5 groups CHA2DS2-VASC (but we will make these comparisons with exploratory purpose), nor to test interactions. Participants: physicians participating to the National Congress of Internal Medicine, physicians participating to courses, professional manifestations. Randomization: randomization will be done on graph type (1 or 2 pictures), duration of risk estimate (1 year and 5 years) and the size of CHA2DS2-VASC risk score (1 to 5), and target prescription (patient or the doctor himself), a total of 40 possibilities. Randomization will be done in blocks of 40. Participants will be asked to decide, depending on the risk chart, if the patient (or himself) will be treated, ignoring the risk of bleeding. The chart will contain the pictogram according to the CHA2DS2-VASC risk score, without communicating the actual score, and the physician will have to make the decision to treat or not, depending on the perceived risk, and not on treatment guidelines. No. questionnaire: first digit = number of risk diagrams (1 or 2); second digit = number of years for which the risk of stroke is calculated (1 or 5); third digit = CHA2DS2-VASC score (1-5). Ex: 253: 2 decision aid diagrams (with and without treatment), with an estimated risk of stroke for the next five years, in a patient with CHA2DS2-VASC score =3. Effect (outcome): decision to treat / not to treat the patient / physician himself, with oral anticoagulants. Statistical analysis: It will look for differences in bivariate analysis, and multivariate = logistic regression (dependent variable = treatment decision, the independent variables = number of charts, period for risk assessment (one or 5 years), prescription target (patient or the physician himself), CHA2DS2-VASC score, time from graduation, medical/teaching grade, working in hospital / ambulatory, the size of the city the physician works in, specialty, gender, age, if the physician has/had someone close with stroke (data from questionnaires).

Interventions

OTHERdecision aid

decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself

Sponsors

Cristian Baicus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
24 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* physicians who prescribe anticoagulant treatment for atrial fibrillation (cardiology, internal medicine, family medicine, hematology) or who deal with patients with stroke (neurology, pathology) or bleeding (gastroenterology)

Exclusion criteria

* physicians who never prescribe anticoagulant treatments, or do not deal with patients with stroke or bleeding because of anticoagulants

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagramsafter seeing the decision aid (5 min)after regarding the risk diagram, the physician will decide to prescribe/take or not the treatment

Other

MeasureTime frameDescription
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years)5 minutesthe proportion of physicians deciding to prescribe OAC after seeing risk estimation on 1 vs 5 years
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself)5 minthe participant physicians were randomized to prescribe to virtual patients or to imagine that the risk seen in the diagram was that of themselves
Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score5 minThe proportion of OAC prescription for the range 1-5 of CHA2D2s-VASC scores. CHA2D2S-VASC risk score ranges from 1-5, with higher scores indicating a greater risk of stroke.

Countries

Romania

Participant flow

Participants by arm

ArmCount
All Participants
all participants in the study (968)
968
Total968

Baseline characteristics

CharacteristicAll Participants
Age, Continuous39 years
Region of Enrollment
Romania
968 participants
Sex: Female, Male
Female
704 Participants
Sex: Female, Male
Male
264 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 4860 / 482
serious
Total, serious adverse events
0 / 4860 / 482

Outcome results

Primary

Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams

after regarding the risk diagram, the physician will decide to prescribe/take or not the treatment

Time frame: after seeing the decision aid (5 min)

ArmMeasureValue (NUMBER)
One DiagramNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams400 participants
Two DiagramsNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Number of Decision Aid Diagrams406 participants
p-value: 0.8395% CI: [-4, 5.4]Chi-squared
Other Pre-specified

Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score

The proportion of OAC prescription for the range 1-5 of CHA2D2s-VASC scores. CHA2D2S-VASC risk score ranges from 1-5, with higher scores indicating a greater risk of stroke.

Time frame: 5 min

ArmMeasureValue (NUMBER)
One DiagramNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score146 participants
Two DiagramsNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score159 participants
CHA2D2S-VASC Risk Score 3Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score164 participants
CHA2D2S-VASC Risk Score 4Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score172 participants
CHA2D2S-VASC Risk Score 5Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score165 participants
Comparison: CHA2D2S-VASC risk score 1 was the referencep-value: 0.03495% CI: [1.2, 17]Chi-squared
p-value: 0.03395% CI: [1.2, 17]Chi-squared
p-value: 0.00395% CI: [4.7, 20.1]Chi-squared
p-value: 0.00995% CI: [3.2, 18.8]Chi-squared
Comparison: CHA2D2S-VASC risk score 1 was the referencep-value: 0.02495% CI: [1.08, 3.07]Regression, Logistic
p-value: 0.0395% CI: [1.06, 2.98]Regression, Logistic
p-value: 0.00295% CI: [1.37, 4.09]Regression, Logistic
p-value: 0.00495% CI: [1.14, 2.56]Regression, Logistic
Other Pre-specified

Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself)

the participant physicians were randomized to prescribe to virtual patients or to imagine that the risk seen in the diagram was that of themselves

Time frame: 5 min

ArmMeasureValue (NUMBER)
One DiagramNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself)442 participants
Two DiagramsNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Target of Prescription (Patient vs. Physician Himself)364 participants
p-value: <0.00195% CI: [10.8, 20]Chi-squared
p-value: <0.00195% CI: [2.25, 4.78]Regression, Logistic
Other Pre-specified

Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years)

the proportion of physicians deciding to prescribe OAC after seeing risk estimation on 1 vs 5 years

Time frame: 5 minutes

ArmMeasureValue (NUMBER)
One DiagramNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years)412 participants
Two DiagramsNumber of Participants Who Prescribed Oral Anticoagulants (OAC) According to the Timeframe for Risk Presentation (1 vs 5 Years)394 participants
Comparison: details provided in protocol;p-value: 0.18795% CI: [-1.3, 8.1]Chi-squared

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026